Help for Alzheimer’s Patients

Trisomy
21 Research Protocol for AD

Very long post on the rational for the prevention of AD. This is NOT specific to DS but works in advanced AD in non DS patients as well. Note, not all substances utilized in TNI for DS are covered here. The science is so amazing. Since so many of us also have family who have or will likely develop AD, I thought you’d find it interesting.

This protocol has been very successful in AD non DS patients as modified (minus some substances used in DS). We have been able to help elderly patients leave nursing homes,regain bowel and bladder control, communicate again and return to their families.

Will someone please post this to the regression group? I can’t get anything to post.

Part one

Curcumin, Resveratrol, EGCG (epigallocatechin-3-gallate), Fisetin, 7,8-Dihydroxyflavone (7,8-DHF), Kaempferol, and Quercetin—can target key Alzheimer’s disease (AD) pathologies. These include amyloid-β (Aβ) production/aggregation/clearance, tau hyperphosphorylation/aggregation, neuroinflammation, oxidative stress, mitochondrial dysfunction, synaptic loss, and impaired neurotrophic signaling. The compounds act pleiotropically with overlapping and complementary mechanisms, potentially explaining observed plaque reduction and functional improvements in patients.
Amyloid-β Pathology (Plaque Formation, Aggregation, and Clearance)
• Inhibition of production: Curcumin inhibits β-secretase (BACE1) activity and downregulates amyloid precursor protein (APP) processing via NF-κB/GSK-3β pathways. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov EGCG promotes non-amyloidogenic α-secretase cleavage of APP (increasing neuroprotective sAPPα) via PKC activation and reduces BACE1. 7,8-DHF suppresses BACE1 expression through TrkB signaling. Quercetin and kaempferol also modulate APP processing and reduce Aβ generation.
• Inhibition of aggregation and fibrillization: Curcumin binds Aβ, inhibits oligomerization/fibril formation, and redirects aggregation toward non-toxic forms; it also labels and disrupts existing plaques. EGCG binds tau and Aβ, destabilizes β-sheets, remodels fibrils into non-toxic oligomers, and inhibits tau aggregation even at substoichiometric levels. Resveratrol reduces Aβ aggregation/toxicity. Fisetin, quercetin, and kaempferol interfere with Aβ fibril formation and β-sheet structures.
• Enhanced clearance: Curcumin promotes microglial phagocytosis of Aβ and upregulates degrading enzymes (e.g., IDE, neprilysin). EGCG enhances autophagy (via AMPK) for protein clearance. Resveratrol activates SIRT1/autophagy and Aβ-degrading enzymes. Fisetin and quercetin boost autophagy and proteasomal activity; senolytic effects of fisetin/quercetin (clearing senescent cells that impair clearance) further aid debris removal. Kaempferol supports clearance indirectly via reduced inflammation/oxidative stress.
This multi-pronged attack on Aβ (reduced production + disaggregation + boosted clearance) provides a strong rationale for plaque reversal.
Tau Pathology (Hyperphosphorylation and Aggregation)
• Curcumin inhibits tau phosphorylation (via GSK-3β suppression) and disaggregates tau oligomers/filaments by disrupting β-sheets. pmc.ncbi.nlm.nih.gov encyclopedia.pub
• EGCG directly inhibits tau aggregation, reduces hyperphosphorylation (kinase inhibition + PP2A activation), and promotes autophagic clearance.
• Resveratrol activates PP2A and SIRT1 to dephosphorylate tau and reduce hyperphosphorylation.
• Fisetin reduces p-tau levels via autophagy (AMPK/SIRT1/TFEB) and inhibits aggregation.
• 7,8-DHF activates TrkB/Akt, leading to GSK-3β inhibition (reducing p-tau at sites like Ser396) and suppresses asparagine endopeptidase (AEP) that generates toxic tau fragments (e.g., tau N368).
• Quercetin and kaempferol reduce p-tau, inhibit aggregation, and protect against tau-induced toxicity (e.g., via HSPB1/NRF2 upregulation for 7,8-DHF/quercetin).
Collectively, these reduce neurofibrillary tangle burden and microtubule destabilization.
Neuroinflammation and Senescence

Part 2

Neuroinflammation and Senescence
• All compounds suppress microglial activation and pro-inflammatory pathways: NF-κB, NLRP3 inflammasome, COX-2, iNOS, and cytokines (TNF-α, IL-1β, IL-6). Curcumin, resveratrol, EGCG, fisetin, quercetin, and kaempferol are potent here. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
• Fisetin and quercetin act as senolytics, selectively clearing senescent cells (e.g., plaque-associated oligodendrocyte progenitors or glia) that drive SASP (senescence-associated secretory phenotype), chronic inflammation, and impaired clearance. This reduces “inflammaging” that exacerbates plaques and tau.
• Resveratrol and curcumin further dampen NLRP3 and promote anti-inflammatory Th2 shifts via SIRT1.
Lower inflammation breaks the vicious cycle with Aβ/tau and supports functional recovery.
Oxidative Stress and Mitochondrial Function
• Potent ROS scavenging and upregulation of antioxidants (SOD, catalase, GSH, Nrf2/HO-1 pathway) by curcumin, resveratrol, EGCG, fisetin, quercetin, and kaempferol. iubmb.onlinelibrary.wiley.com
• Mitochondrial protection: Resveratrol (SIRT1/AMPK), curcumin, and others preserve membrane potential, reduce ROS-induced damage, and improve bioenergetics. This mitigates Aβ/tau-driven mitochondrial dysfunction, a key driver of neuronal loss.

Part 3

Synaptic Plasticity, Neurotrophism, and Neuroprotection
• BDNF/TrkB axis: 7,8-DHF is a direct TrkB agonist mimicking BDNF, activating downstream PI3K/Akt, ERK/CREB, and increasing synaptic proteins/LTP while preventing synapse loss. Curcumin, resveratrol, fisetin, quercetin, and kaempferol upregulate BDNF expression/signaling, supporting neurogenesis, synaptic repair, and cognition.
• Anti-apoptotic effects: Upregulation of Bcl-2, downregulation of Bax/caspases via Akt, Nrf2, and other pathways across the stack.
• Overall neurorescue: Enhanced autophagy/mitophagy (EGCG, resveratrol, fisetin), reduced excitotoxicity, and improved BBB integrity.
Synergistic Potential of the Combination
These molecules hit overlapping (e.g., NF-κB/Nrf2 for inflammation/oxidative stress) and distinct nodes (TrkB by 7,8-DHF; strong senolysis by fisetin/quercetin; direct fibril remodeling by EGCG/curcumin). Polyphenols often show additive/synergistic effects in models (e.g., enhanced autophagy, better Aβ/tau clearance, amplified BDNF signaling). The stack addresses the multifactorial nature of AD—amyloid, tau, inflammation, oxidation, and synaptic failure—more comprehensively than single agents, potentially explaining plaque reduction and clinical functional gains (cognition, daily activities) via restored neuronal health and reduced burden.
Notes on translation: Many effects are demonstrated in vitro, in AD transgenic mice (e.g., 5XFAD, APP/PS1, tau models), and some human biomarker studies (e.g., resveratrol stabilizing CSF Aβ/inflammation markers). Bioavailability varies (curcumin and EGCG often need enhancers like piperine or formulations for better brain penetration), but clinical use in combinations has shown promise. Dosing, formulation, and patient-specific factors matter for efficacy.